Efficacy and Tolerability of ABB I5 Prebiotic and ABB C22 Postbiotics for the Management of Constipation and Gastrointestinal Well-being: a Pilot Trial

Efficacy and Tolerability of ABB I5 Prebiotic and ABB C22 Postbiotics for the Management of Constipation and Gastrointestinal Well-being: a Pilot Trial

In this study, we aim at assessing the benefits of dietary supplementation with ABB i5 and ABB C24, a combination of the the prebiotic ABB i5 and the postbiotic ABB C22, on the gut microbiota of people with constipation and on their gastrointestinal well-being.

Inclusion Criteria:

• Subjects who require hospitalization
• Constipation defined as the Rome IV criteria for constipation
• Patients with the ability to take the study product orally

Exclusion Criteria:

• History of allergy, idiosyncrasy, hypersensitivity or adverse reactions to the active principle or to any of the excipients.
• History or evidence of any medical conditions or medication used that, in the opinion of the principal investigator, could affect the safety of the subjects or interfere with the study evaluations
• Patients last palliative care en stage of "end of life" or "terminal"
• Amytriptilin (anti-depressive) and masalazine (anti-inflammatory) treatment
• Laxatives
• Antibiotic treatment in the previous 2 weeks
• Patients with IBS or any other gastrointestinal conditions that maybe the cause of the constipation